TVRD profile · all as-reported value updates
Tvardi Therapeutics, Inc. (TVRD) as-reported value updates
Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.
Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.
Ledger table figure
| Metric | FY | Earliest XBRL-filed value | Currently on file | Difference | Difference % | Label | Filing links | Notes |
|---|---|---|---|---|---|---|---|---|
| Stockholders' equity | 2023 | 57,085,000 | -62,058,000 | -119,143,000 | -191.99% | revised comparative figure | 0001558370-24-002609 0001104659-26-037729 | 3 filed observations examined for this concept and period. |
| Stockholders' equity | 2024 | -4,593,000 | -91,131,000 | -86,538,000 | -94.96% | revised comparative figure | 0001558370-25-002705 0001104659-26-037729 | 2 filed observations examined for this concept and period. |
| Operating cash flow | 2024 | -60,917,000 | -18,305,000 | 42,612,000 | +69.95% | revised comparative figure | 0001558370-25-002705 0001104659-26-037729 | 2 filed observations examined for this concept and period. |
| Net income | 2024 | -70,867,000 | -29,397,000 | 41,470,000 | +58.52% | revised comparative figure | 0001558370-25-002705 0001104659-26-037729 | 2 filed observations examined for this concept and period. |
| Operating income | 2024 | -58,383,000 | -28,107,000 | 30,276,000 | +51.86% | revised comparative figure | 0001558370-25-002705 0001104659-26-037729 | 2 filed observations examined for this concept and period. |
| Assets | 2024 | 43,827,000 | 35,199,000 | -8,628,000 | -19.69% | revised comparative figure | 0001558370-25-002705 0001104659-26-037729 | 2 filed observations examined for this concept and period. |
| Cash and cash equivalents | 2024 | 37,903,000 | 31,614,000 | -6,289,000 | -16.59% | revised comparative figure | 0001558370-25-002705 0001104659-26-037729 | 2 filed observations examined for this concept and period. |
| Liabilities | 2024 | 48,420,000 | 40,827,000 | -7,593,000 | -15.68% | revised comparative figure | 0001558370-25-002705 0001104659-26-037729 | 2 filed observations examined for this concept and period. |